Inter Parfums adjusts 2008 guidance
This article was originally published in The Rose Sheet
Executive Summary
Inter Parfum announces Nov. 24 that it is revising its 2008 guidance, now calling for net sales of approximately $445 mil. and net income of approximately $25 mil., versus previously projected $460 mil. and $26.8 mil., respectively. CFO Russell Greenberg says company expected strength of new product launches and existing brands to enable it to reach original 2008 guidance; however, "the very challenging economic environment that has manifested itself over the last few weeks brings doubt to that expectation." While Inter Parfums acknowledges that upcoming year will continue to be challenging, CEO Jean Madar says firm will continue to invest in new products. In 2009 the company plans to launch men's version of Burberry The Beat, Lanvin L'Homme Sport line and first bebe fragrance
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.